THE EFFECT OF LOW-DOSE OKT3 MONOCLONAL-ANTIBODY THERAPY ON K562 CYTOTOXICITY IN HUMAN CANCER-PATIENTS
- Authors:
- Published online on: September 1, 1994 https://doi.org/10.3892/ijo.5.3.675
- Pages: 675-681
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Low concentrations of monoclonal antibodies (mAb) specific for the CD3 component of the T cell receptor complex (TcR) may be both immunosuppressive or potent activators of T cell function in vitro depending upon the experimental situation. The anti-CD3 mAb OKT3 is imnmunosuppressive at high doses (5 mg/day for 10 to 14 days) in transplant patients. We undertook a preliminary study to investigate the effect of a single intravenous injection of 50 mu g to 0.5 mu g of OKT3 mAb in cancer patients. OKT3 modulated cytotoxicity with minimal clinical toxicity at low doses and may be of use in cancer immunotherapy protocols.